Who is sponsoring NCT02674243?

NCT02674243 is sponsored by Chiang Mai University.

What drugs are being tested in NCT02674243?

Interventions in NCT02674243: Iodopovidone solution, Talc.

What condition does NCT02674243 study?

NCT02674243 studies Malignant Pleural Effusion.

Is NCT02674243 still recruiting?

NCT02674243 is currently completed. Last updated 21 January 2020.

Last reviewed 2020-01-21 · How we verify

NCT02674243

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion: a Randomized Controlled Trial Study

Completed Phase 3 Last updated 21 January 2020

What this trial tests

Phase 3 trial testing Iodopovidone solution in Malignant Pleural Effusion in 60 participants. Completed in 1 December 2019.

Timeline

1 November 2015

Primary endpoint
1 December 2019

1 December 2019

Quick facts

Lead sponsor	Chiang Mai University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	1 November 2015
Primary completion	1 December 2019
Estimated completion	1 December 2019
Sites	1 location across Thailand

Drugs / interventions tested

Iodopovidone solution
Talc (TALC) — full drug profile →

Conditions studied

Malignant Pleural Effusion — all drugs for Malignant Pleural Effusion →

Sponsor

Chiang Mai University

Who can join

18 and older, any sex, with Malignant Pleural Effusion. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Success of treatment
Time frame: 7 days
Success of treatment defined as chest drain can be removed within 1 week after intervention

Sponsor's own description

This is prospective randomized control trial study. The aim of this study is to evaluate the efficacy of Iodopovidone solution for pleurodesis in palliative malignant pleural effusion (MPE) patients comparing to Talc. All adult patients who diagnosed MPE by cytology regardless primary tumor between December 1, 2015 and November 29, 2016 at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand will be enrolled in this study. The inform and consent will be applied in all patients before treatment. Patients will be randomized to two groups; Iodopovidone group (intervention group) and Talc group (control group)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Malignant Pleural Effusion

Currently open trials in the same condition.

NCT06421610 — OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. · Phase 1 · recruiting
NCT05620329 — UNC Pleural Fluid Registry · recruiting

Other Chiang Mai University trials

Trials by the same sponsor.

NCT07366775 — A Telenursing Program to Support Diabetes Self-Management · NA · active not recruiting
NCT07032610 — Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents · not yet recruiting
NCT06978621 — Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV · Phase 3 · recruiting
NCT06905041 — Preoperative Anemia Affected to Postoperative Outcomes in Liver Resection · not yet recruiting
NCT07476404 — Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02674243 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chiang Mai University
Last refreshed: 21 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02674243.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing